#United States #Kessler Topaz #FDA #Radnor, Pennsylvania #uniQure N.V.

Kessler Topaz Meltzer Investigates uniQure N.V.

Kessler Topaz Meltzer & Check, LLP, a prominent plaintiff-side law firm, is currently looking into potential violations of federal securities laws concerning investors of uniQure N.V. (NASDAQ: QURE). This scrutiny comes in light of significant stock price declines experienced by the company following recent announcements.

Background of the Investigation

On November 3, 2025, uniQure made headlines when it revealed that the FDA had indicated that the data for its investigational gene therapy AMT-130—intended for Huntington's disease—did not present sufficient evidence for a Biologics License Application (BLA) submission. This unexpected feedback suggests that the FDA currently does not recognize data from the earlier Phase I/II studies of AMT-130 as adequate for progressing with the BLA submission. Consequently, investors were left in limbo regarding the timeline of this critical submission.

Impact on Stock Prices

The announcement had a dramatic effect on uniQure’s stock pricing, which tumbled over 50%, plummeting from a closure of $67.69 on October 31, 2025, to just $34.29 by the close of trading on November 3, 2025. This sharp decline has understandably caused alarm among the investor community, spurring many to investigate their rights following this significant loss.

What This Means for Investors

Investors who have faced substantial losses due to the stock’s dramatic decline are encouraged to reach out to Kessler Topaz Meltzer & Check, LLP to explore their legal options. The firm has been at the forefront of securing protections for investors, particularly in cases involving securities fraud. Those interested in participating in the investigation can complete an online form or directly contact the firm’s attorney, Jonathan Naji, via email or phone.

About Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP specializes in litigating securities-fraud class actions and supporting global investor protection. The firm represents individual investors alongside larger institutions including pension funds, asset managers, and international investors. Known for its robust legal service in the securities sector, Kessler Topaz has generated some of the most significant recoveries in securities litigation history. The firm has gained multiple accolades, affirming its status as a leading entity within the legal landscape.

With offices located in Pennsylvania and California, Kessler Topaz continues to operate globally, remaining committed to supporting investor rights across various jurisdictions.

Conclusion

As developments unfold, uniQure investors are urged to stay informed about their investment and legal rights. In light of the recent FDA feedback and the subsequent decline in stock prices, seeking legal advice could prove beneficial for those with existing claims. To learn more about the ongoing investigation or to get in touch with Kessler Topaz Meltzer, investors need to be proactive and informed, thereby safeguarding their financial wellbeing.